Search
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigational[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136] … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.
Products: ARIPIPRAZOLO EGFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency.
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency at reducing pulmonary viral loads in animal models.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900]
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. … It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLCategories: Complex MixturesBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalbrexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-E